---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-067084"
form_type: "8-K"
ticker: null
cik: "0001499785"
company_name: "Tengjun Biotechnology Corp."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:49:58.008127+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tengjun Biotechnology restates FY2022 financials, appoints new CEO/CFO after prior officer's death

## Summary
- Board determined FY2022 financial statements unreliable due to accounting errors; restatement via amended 10-K planned.
- Previous Director, CEO, and CFO Xianchang Ma passed away on August 3, 2023.
- Ms. Caihong Qu appointed as Director, interim CEO, and CFO effective August 10, 2023.
- Ms. Qu (age 48) is the late wife of Mr. Ma and legal rep of Jinxiang County Kanglong Water Purification Equipment Co., Ltd.

## SEC filing metadata
- accession: 0001213900-23-067084
- form_type: 8-K
- cik: 0001499785
- company_name: Tengjun Biotechnology Corp.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1499785/000121390023067084/0001213900-23-067084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1499785/000121390023067084/ea183436-8k_tengjun.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-067084
- JSON: https://secwatch.observer/filing/0001213900-23-067084.json
- Plain text: https://secwatch.observer/filing/0001213900-23-067084.txt

## Key facts
- Auditor Changes
  Tengjun Biotechnology Corp. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: the Company’s Board of Directors (the “Board”) concluded that the Company’s previously issued financial statements, contained within its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023067084/0001213900-23-067084-index.htm
- Executive change
  Caihong Qu was appointed as Interim Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..
  - Action: appointed
  - Role: Interim Chief Executive Officer and Chief Financial Officer
  source text: On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company, until the next annual meeting of the Corporation’s shareholders, and until her successor is elected and qualified or until her prior disqualification.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023067084/0001213900-23-067084-index.htm
- Executive change
  Xianchang Ma departed as Director, Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..
  - Action: passed away
  - Role: Director, Chief Executive Officer and Chief Financial Officer
  source text: Ms. Qu is the late wife of Mr. Xianchang Ma, our previous Director, CEO and CFO, who passed away on August 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023067084/0001213900-23-067084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.